Litcius/Paper detail

Is Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Superior Even to Lenvatinib? A Matching-Adjusted Indirect Comparison

Andrea Casadei‐Gardini, Toshifumi Tada, Shigeo Shimose, Takashi Kumada, Takashi Niizeki, Stefano Cascinu, Alessandro Cucchetti

2021Targeted Oncology22 citationsDOI

Topics & Concepts

AtezolizumabMedicineLenvatinibBevacizumabHepatocellular carcinomaOncologyInternal medicineCarcinomaCancerChemotherapyPembrolizumabImmunotherapySorafenibHepatocellular Carcinoma Treatment and PrognosisCholangiocarcinoma and Gallbladder Cancer StudiesColorectal Cancer Treatments and Studies
Is Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Superior Even to Lenvatinib? A Matching-Adjusted Indirect Comparison | Litcius